



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 5/19/06 Signature: Allison M. Deverman Vliet  
(Allison M. Deverman Vliet)

*APW*  
Docket No.: ALEX-P03-060  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Bowdish et al.

Application No.: 10/736,188

Confirmation No.: 4387

Filed: December 15, 2003

Art Unit: 1646

For: POLYPEPTIDES AND ANTIBODIES  
DERIVED FROM CHRONIC  
LYMPHOCYTIC LEUKEMIA CELLS AND  
USES THEREOF

Examiner: Not Yet Assigned

### INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications.

Documents on the attached form PTO/SB/08 are not supplied because they were previously submitted to the Office in a prior application number 10/379,151, filed March 4, 2003 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ALEX-P03-060.

Dated: 5/19/06

Respectfully submitted,

By Anita Varma  
Anita Varma  
Registration No.: 43,221  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/736,188
Sheet	1	of	4	Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1646
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	ALEX-P03-060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA	US-5,225,539	07-06-1993	Winter		
AB	US-4,376,110	03-08-1983	David et al.		
AC	US-5,427,908	06-27-1995	Dower et al.		
AD	US-5,508,717	04-16-1996	Miller		
AE	US-5,403,484	04-04-1995	Ladner et al.		
AF	US-5,223,409	06-29-1993	Ladner et al.		
AG	US-5,780,279	07-14-1998	Matthews et al.		
AH	US-5,571,698	11-05-1996	Ladner et al.		
AI	US-6,040,136	03-21-2000	Garrard et al.		
AJ	US-3,940,475	02-24-1976	Gross		
AK	US-4,289,747	09-15-1981	Chu		
AL	US-5,580,717	12-03-1996	Dower et al.		
AM	US-5,434,131	07-18-1995	Linsley et al.		
AN	US-5,916,560	06-29-1999	Larsen et al.		
AO	US-6,338,851	01-15-2002	Gorczynski		
AP	US-2002/0192215	12-19-2002	Hoek et al.		
AQ	US-2005/0107214	05-19-2005	Gorczynski et al.		
AR	US-2004/0054145	03-18-2004	Gorczynski		
AS	US-2004/0018972	01-29-2004	Gorczynski et al.		
AT	US-6,652,858	11-25-2003	Gorczynski et al.		
AU	US-6,984,625	01-10-2006	Gorczynski		
AV	US-6,955,811	10-18-2005	Gorczynski et al.		
AW	US-2005/0048069	03-03-2005	Gorczynski et al.		
AX	US-6,749,854	06-15-2004	Gorczynski et al.		
AY	US-2004/0198661	10-07-2004	Bowdish et al.		
AZ	US-2002/01683364	11-14-2002	Gorczynski et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	WO-9708320A1		03-06-1997	Morphosys Gesellschaft MBH	
BB	WO-8806630A1		09-07-1988	Genex Corp.	
BC	WO-9215679A1		09-17-1992	Protein Engineering Corp.	
BD	WO-9627011A1		09-06-1996	Genentech, Inc.	
BE	WO-8403508A1		09-13-1984	Dragoco Gerberding & Co. GMBH	
BF	WO-8503508A1		08-15-1985	Cetus Corp.	
BG	WO-04078937A2		09-16-2004	Alexion Pharmaceuticals, Inc.	
BH	WO-03025202A2		03-27-2003	Alexion Pharmaceuticals, Inc.	
BI	WO-97021450A		06-19-1997	Brigham and Women's Hospital	
BJ	WO-99024565		05-20-1999	Gorczynski, R.M.	
BK	WO-02095030		11-28-2002	Transplantation Tech, Inc.	
BL	WO-02011762A2		02-14-2002	Gorczynski et al.	

Examiner Signature		Date Considered
--------------------	--	-----------------

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/736,188
				Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	ALEX-P03-060

BM	WO-02042332A2	05-30-2002	Transplantation Technologies	
----	---------------	------------	------------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<input type="checkbox"/> <input type="checkbox"/>	
	CA	AUCHINCLOSS, "Strategies to Induce Tolerance," Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995).		
	CB	BARCLAY, "Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens," Immunology, 44:727-736(1981).		
	CC	BARCLAY and WARD, "Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2," European J. Biochemistry, 129:447-458(1982).		
	CD	BORRIELLO et al., "Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX - 2 membrane glycoprotein," Mammalian Genome, 9(2):114-118(1998).		
	CE	BORRIELLO et al., "MRC OX-2 Defines a Novel T Cell Costimulatory Pathway," J. Immunol., 158:4549-4554(1997).		
	CF	CHEN et al., "Cloning and characterization of the murine homologue of the rat/human MRC OX - 2 gene," Biochimica et Biophysica Acta, 1362(1):6-10(1997).		
	CG	GORCZYNSKI et al., "Increased expression of the novel molecule OX - 2 is involved in prolongation of murine renal allograft survival," Transplantation, 65(8):1106-1114(1998).		
	CH	GORCZYNSKI et al., "An Immunoadhesin Incorporating the Molecule OX-2 Is a Potent Immunosuppressant That Prolongs Allo- and Xenograft Survival," J. Immunol., 163:1654-1660(1999).		
	CI	PRESTON et al., "The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages", European J. of Immunol., 27(8):1911-1918(1997).		
	CJ	BACH, "Immunosuppressive therapy of autoimmune diseases," Immunology Today, 14(6)322-326(1993).		
	CK	BOHEN, S.P., "Variation in gene expression patterns in follicular lymphoma and the response to rituximab," PNAS, 100(4):1926-1930(2003).		
	CL	BOON, Thierry, "Toward a Genetic Analysis of Tumor Rejection Antigens," Advances in Cancer Res., 58:177-210(1992).		
	CM	BRODERICK et al., "Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis," Am. J. of Pathology, 161(5):1669-1677(2002).		
	CN	CLARK, D.A., "Intralipid as Treatment for Recurrent Unexplained Abortion?", Am. J. of Reprod. Immunol., 32:290-293(1994).		
	CO	CLARK et al., Amer. Soc. for Reprod. Medicine, 55th Annual Meeting (1999). Abstract Only.		
	CP	CLARK et al., "The OX-2 Tolerance Signal Molecule at the Fetalmaternal Interface Determines Pregnancy Outcome," Amer. Journal of Reprod Immunol., 43:326(2000). Abstract Only.		
	CQ	CHAOUAT and CLARK, "FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer.		

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/736,188
				Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	ALEX-P03-060

	J. of Reprod. Immunol., 45:108-115(2001).				
CR	CLARK et al., "Fg12 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2," Mol. Human Reprod., 7:185-194(2001).				
CS	COHEN, P.L., "Systemic Autoimmunity," in Fundamental Immunology, Fourth edition, W.E. Paul, Editor, Lippincott-Raven Publishers, Philadelphia, Ch. 33, p. 1067-1088(1999).				
CT	DICK et al., "Control of Myeloid Activity During Retinal Inflammation," J. of Leukocyte Bio., 74:161-166(2003).				
CU	GORCZYNSKI et al., "Does Successful Allopregnancy Mimic Transplantation Tolerance?", Graft, 4(5):338-345(2001).				
CV	HOEK, et al., "Down-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200)," Science, 290:1768-1771(2000).				
CW	HUANG, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis," Pharmacol. Therapeutics, 86:201-215(2000).				
CX	JAIN, "The next frontier of molecular medicine: Delivery of therapeutics," Nature Medicine, 4(6):655-657(1998).				
CY	KEIL et al., American Society for Reproductive Immunology XXIst Annual Meeting, June 9-12, 2001, Chicago, IL., Page 343. Abstract Only.				
CZ	KIM et al., "Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation," Cancer Res., 61:2031-2037(2001).				
CA1	KJAERGAARD et al., "Therapeutic Efficacy of OX-40 Receptor Antibody Depends on Tumor Immunogenicity and Anatomic Site of Tumor Growth," Cancer Res. 60:5514-5521(2000).				
CB1	PARDOLL, Drew, "Therapeutic Vaccination for Cancer," Clin. Immunol., 95(1):S44-S62(2000).				
CC1	RAGHEB et al., "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2", Immunol. Letters, 68:311-315(1999).				
CD1	ROMAGNANI, Sergio., "Short Analytical Review: TH1 and TH2 in Human Diseases," Clin. Immunol. Immunopath., 80(3):225-235(1996).				
CE1	ROSENWALD et al., "Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia," J. of Exp. Medicine, 194(11):1639-1647(2001).				
CF1	STEINMAN, Lawrence., "Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy," Neuron, 24:511-514(1999).				
CG1	TANGRI and RAGHUPATHY, "Expression of Cytokines in Placentas of Mice Undergoing Immunologically Mediated Spontaneous Fetal Resorptions," Biology of Reprod., 49:850-856(1993).				
CH1	TODER et al., "Mouse Model for the Treatment of Immune Pregnancy Loss," Am. J. of Reprod. Immunol., 26:42-46(1991).				
CI1	MJAALAND et al., "Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies", Eur. J. Immunol., 20:1457-1461(1990).				
CJ1	BARCLAY et al., "Neuronal/Lymphoid Membrane Glycoprotein MRC OX-2 is a Member of the Immunoglobulin Superfamily with a Light-Chain-Like Structure," Biochem. Soc. Symp., 51:149-157(1985).				
CK1	MCCAUGHAN et al., "Characterization of the Human Homolog of the Rat MRC OX-2 Membrane Glycoprotein," Immunogenetics, 25:329-335(1987).				
CL1	Paterson et al., "Antigens of Activated Rat T Lymphocytes Including A Molecule of 50,000 Mr Detected Only on CD4 Positive T Blasts," Molecular Immunology, 24(12):1281-1290(1987).				
CM1	HEANEY et al., "Severe asthma treatment: need for characterising patients," Lancet, 365:974-976(2005).				
CN1	GORCZYNSKI, "CD200 and its receptors as targets for immunoregulation," Current Opinion in				

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	10/736,188
				Filing Date	December 15, 2003
				First Named Inventor	Katherine S. Bowdish
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	ALEX-P03-060

		Investigational Drugs, 6:483-488(2005).	
	CO1	Ni et al., "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival", FASEB Journal 13(5):A983(1999). Abstract Only.	
	CP1	CLARK et al., "Labile CD200 tolerance signal important in transfusion-related immunomodulation (TRIM) prevention of recurrent miscarriages," Amer. J. Reprod. Immunol., 45:361(2001). Abstract Only.	
	CQ1	GORCZYNSKI, R.M., "Evidence for an Immunoregulatory Role of OX2 with Its Counter Ligand (OX2L) in the Regulation of Transplant Rejection, Fetal Loss, Autoimmunity and Tumor Growth," Arch. Immunol. et Ther. Exp., 49(4):303-309(2001).	
	CR1	NATHAN and MULLER, "Putting the Brakes on innate immunity: a regulatory role for CD200?", Nat Immunol., 2(1):17-19(2001).	
	CS1	CLARK et al., "Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal," Seminars in Immunol., 13(4):255-263(2001).	
	CT1	STUART et al., "Monkeying Around with Collagen Autoimmunity and Arthritis," Lab. Invest., 54(1):1-3(1986).	
	CU1	GORCZYNSKI and MARSDEN, "Modulation of CD200 receptors as a novel method of immunosuppression," Expert Opin. Ther. Patents, 13(5):711-715(2003). See also WIPO Patent No. WO02095030 assigned to Transplantation Tech, Inc.	
	CV1	TANG et al., "Pathogenesis of collagen-induced arthritis: modulation of disease by arthritogenic T-Cell epitope location, Immunology, 113:384-391.	
	CW1	MYERS et al., "Characterization of a Peptide Analog of a Determinant of Type II Collagen that Suppresses Collagen-Induced Arthritis," J. of Immunology, 161:3589-3595(1998).	
	CX1	GORCZYNSKI et al., "Anti-CD200R Ameliorates Collagen-Induced Arthritis in Mice," Clinical Immunol., 104(3):256-264(2002).	
	CY1	CHITNIS et al., "The Role of CD200 in Immune-Modulation and Neural Protection in EAE," Abstract, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, July 21, 2004. Abstract Only.	
	CZ1	BARCLAY et al., "CD200 and membrane protein interactions in the control of myeloid cells," Trends in Immunology, 23(6):2002.	
	CA2	GORCZYNSKI et al., "Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice," Clin. Exp. Immunol., 126:220-229(2001).	
	CB2	ALIZADEH et al., "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling," Nature, 403:503-511(2000).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/736,188

Attorney Docket No.: ALEX-P03-060

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 5/19/2006  
Date

Allison M. Deverman Vietor

Signature

Allison M. Deverman Vietor

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (93 References) (4 pages)  
Return Receipt Postcard